Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749356 | 0.97 | AKR1C3 (0.52) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL5192816 | 0.88 | KDM4E (0.52) | AKR1C3AKR1C2KDM4EMAPTMAPK1 | |
| SCHEMBL268414 | 0.87 | TDP1 (0.62) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL147187 | 0.85 | AKR1C3 (0.63) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL1632528 | 0.85 | ALDH1A1 (0.57) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL7688039 | 0.85 | MEN1 (0.45) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL28098069 | 0.85 | TDP1 (0.45) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL11773334 | 0.84 | AKR1C3 (0.61) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL2839286 | 0.84 | KCNMA1 (0.53) | AKR1C3AKR1C2KDM4EMAPTRAB9A | |
| SCHEMBL1567614 | 0.84 | NPC1 (0.53) | AKR1C3AKR1C2KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | AKR1C3 1010/4885AKR1C2 1043/4885KDM4E 4265/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | AKR1C3 1010/4885AKR1C2 1043/4885KDM4E 4265/4885 |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | AKR1C3 460/4885AKR1C2 605/4885KDM4E 1626/4885 |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | AKR1C3 460/4885AKR1C2 605/4885KDM4E 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.